Sonoma Pharmaceuticals, Inc.
SNOA
$1.33
$0.010.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 47.00% | 36.68% | 26.83% | 25.02% | 17.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.00% | 36.68% | 26.83% | 25.02% | 17.43% |
| Cost of Revenue | 44.17% | 37.30% | 22.53% | 26.73% | 18.30% |
| Gross Profit | 51.66% | 35.68% | 34.49% | 22.31% | 16.01% |
| SG&A Expenses | 4.69% | 3.31% | -3.75% | -0.19% | -1.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.79% | 22.18% | 11.13% | 12.53% | 6.99% |
| Operating Income | 61.29% | 33.67% | 38.02% | 27.06% | 21.62% |
| Income Before Tax | 20.46% | -17.61% | 7.70% | 8.61% | 31.13% |
| Income Tax Expenses | -160.30% | -144.36% | -900.00% | 205.36% | 2,470.59% |
| Earnings from Continuing Operations | 36.32% | 8.16% | 10.09% | 5.62% | 22.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.32% | 8.16% | 10.09% | 5.62% | 22.04% |
| EBIT | 61.29% | 33.67% | 38.02% | 27.06% | 21.62% |
| EBITDA | 63.65% | 34.99% | 39.07% | 27.53% | 21.66% |
| EPS Basic | 50.30% | 37.87% | 48.46% | 55.28% | 75.57% |
| Normalized Basic EPS | 36.55% | 20.71% | 48.19% | 57.57% | 77.65% |
| EPS Diluted | 50.30% | 37.87% | 48.46% | 55.28% | 75.57% |
| Normalized Diluted EPS | 36.55% | 20.71% | 48.19% | 57.57% | 77.65% |
| Average Basic Shares Outstanding | 55.42% | 35.73% | 60.67% | 99.00% | 137.49% |
| Average Diluted Shares Outstanding | 55.42% | 35.73% | 60.67% | 99.00% | 137.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |